Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt No Debt
IMGN's Cash to Debt is ranked higher than
87% of the 1438 Companies
in the Global Biotechnology industry.

( Industry Median: 51.73 vs. IMGN: No Debt )
IMGN' s 10-Year Cash to Debt Range
Min: 0.39   Max: 50356.33
Current: No Debt

0.39
50356.33
Equity to Asset 0.60
IMGN's Equity to Asset is ranked higher than
68% of the 1086 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. IMGN: 0.60 )
IMGN' s 10-Year Equity to Asset Range
Min: 0.27   Max: 0.95
Current: 0.6

0.27
0.95
Interest Coverage No Debt
IMGN's Interest Coverage is ranked higher than
99% of the 650 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. IMGN: No Debt )
IMGN' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 4
Z-Score: 2.68
M-Score: -3.52
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -97.24
IMGN's Operating margin (%) is ranked higher than
72% of the 1163 Companies
in the Global Biotechnology industry.

( Industry Median: -91.29 vs. IMGN: -97.24 )
IMGN' s 10-Year Operating margin (%) Range
Min: -3860   Max: -6.81
Current: -97.24

-3860
-6.81
Net-margin (%) -97.95
IMGN's Net-margin (%) is ranked higher than
71% of the 1163 Companies
in the Global Biotechnology industry.

( Industry Median: -76.91 vs. IMGN: -97.95 )
IMGN' s 10-Year Net-margin (%) Range
Min: -3980   Max: -2.13
Current: -97.95

-3980
-2.13
ROE (%) -82.48
IMGN's ROE (%) is ranked higher than
58% of the 1318 Companies
in the Global Biotechnology industry.

( Industry Median: -31.17 vs. IMGN: -82.48 )
IMGN' s 10-Year ROE (%) Range
Min: -257.81   Max: -2.3
Current: -82.48

-257.81
-2.3
ROA (%) -43.94
IMGN's ROA (%) is ranked higher than
63% of the 1445 Companies
in the Global Biotechnology industry.

( Industry Median: -25.65 vs. IMGN: -43.94 )
IMGN' s 10-Year ROA (%) Range
Min: -129.41   Max: -1.79
Current: -43.94

-129.41
-1.79
ROC (Joel Greenblatt) (%) -546.48
IMGN's ROC (Joel Greenblatt) (%) is ranked higher than
70% of the 1405 Companies
in the Global Biotechnology industry.

( Industry Median: -346.25 vs. IMGN: -546.48 )
IMGN' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -666.37   Max: -48.97
Current: -546.48

-666.37
-48.97
Revenue Growth (3Y)(%) 35.70
IMGN's Revenue Growth (3Y)(%) is ranked higher than
94% of the 773 Companies
in the Global Biotechnology industry.

( Industry Median: 2.50 vs. IMGN: 35.70 )
IMGN' s 10-Year Revenue Growth (3Y)(%) Range
Min: -36.1   Max: 133.1
Current: 35.7

-36.1
133.1
EBITDA Growth (3Y)(%) -0.80
IMGN's EBITDA Growth (3Y)(%) is ranked higher than
77% of the 823 Companies
in the Global Biotechnology industry.

( Industry Median: -2.40 vs. IMGN: -0.80 )
IMGN' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -71.2   Max: 282.6
Current: -0.8

-71.2
282.6
EPS Growth (3Y)(%) -0.80
IMGN's EPS Growth (3Y)(%) is ranked higher than
79% of the 802 Companies
in the Global Biotechnology industry.

( Industry Median: -5.40 vs. IMGN: -0.80 )
IMGN' s 10-Year EPS Growth (3Y)(%) Range
Min: -75.7   Max: 263.4
Current: -0.8

-75.7
263.4
» IMGN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

IMGN Guru Trades in Q1 2014

PRIMECAP Management 12,675,427 sh (unchged)
» More
Q2 2014

IMGN Guru Trades in Q2 2014

Jim Simons 415,440 sh (New)
PRIMECAP Management 11,922,396 sh (-5.94%)
» More
Q3 2014

IMGN Guru Trades in Q3 2014

PRIMECAP Management 11,918,396 sh (-0.03%)
Jim Simons 370,446 sh (-10.83%)
» More
Q4 2014

IMGN Guru Trades in Q4 2014

PRIMECAP Management 12,127,073 sh (+1.75%)
Jim Simons 162,840 sh (-56.04%)
» More
» Details

Insider Trades

Latest Guru Trades with IMGN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 11.40
IMGN's P/B is ranked higher than
50% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 7.01 vs. IMGN: 11.40 )
IMGN' s 10-Year P/B Range
Min: 1.68   Max: 16.54
Current: 11.4

1.68
16.54
P/S 11.68
IMGN's P/S is ranked higher than
70% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 37.00 vs. IMGN: 11.68 )
IMGN' s 10-Year P/S Range
Min: 2.83   Max: 97.63
Current: 11.68

2.83
97.63
EV-to-EBIT -10.40
IMGN's EV-to-EBIT is ranked lower than
55% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. IMGN: -10.40 )
IMGN' s 10-Year EV-to-EBIT Range
Min: -43.7   Max: -2.2
Current: -10.4

-43.7
-2.2
Current Ratio 5.82
IMGN's Current Ratio is ranked higher than
77% of the 1401 Companies
in the Global Biotechnology industry.

( Industry Median: 4.40 vs. IMGN: 5.82 )
IMGN' s 10-Year Current Ratio Range
Min: 0.51   Max: 60.86
Current: 5.82

0.51
60.86
Quick Ratio 5.72
IMGN's Quick Ratio is ranked higher than
78% of the 1401 Companies
in the Global Biotechnology industry.

( Industry Median: 4.25 vs. IMGN: 5.72 )
IMGN' s 10-Year Quick Ratio Range
Min: 0.51   Max: 60.86
Current: 5.72

0.51
60.86
Days Sales Outstanding 15.31
IMGN's Days Sales Outstanding is ranked higher than
95% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 139.31 vs. IMGN: 15.31 )
IMGN' s 10-Year Days Sales Outstanding Range
Min: 1.53   Max: 730
Current: 15.31

1.53
730

Valuation & Return

vs
industry
vs
history
Price/Net Cash 15.50
IMGN's Price/Net Cash is ranked higher than
68% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 109.90 vs. IMGN: 15.50 )
IMGN' s 10-Year Price/Net Cash Range
Min: 0.9   Max: 179
Current: 15.5

0.9
179
Price/Net Current Asset Value 14.80
IMGN's Price/Net Current Asset Value is ranked higher than
67% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 45.70 vs. IMGN: 14.80 )
IMGN' s 10-Year Price/Net Current Asset Value Range
Min: 0.85   Max: 78.15
Current: 14.8

0.85
78.15
Price/Tangible Book 11.20
IMGN's Price/Tangible Book is ranked higher than
55% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 10.60 vs. IMGN: 11.20 )
IMGN' s 10-Year Price/Tangible Book Range
Min: 0.81   Max: 40
Current: 11.2

0.81
40
Price/Median PS Value 0.80
IMGN's Price/Median PS Value is ranked higher than
91% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 3.10 vs. IMGN: 0.80 )
IMGN' s 10-Year Price/Median PS Value Range
Min: 0.23   Max: 12.5
Current: 0.8

0.23
12.5
Earnings Yield (Greenblatt) -9.60
IMGN's Earnings Yield (Greenblatt) is ranked higher than
56% of the 1393 Companies
in the Global Biotechnology industry.

( Industry Median: -5.90 vs. IMGN: -9.60 )
IMGN' s 10-Year Earnings Yield (Greenblatt) Range
Min: -15.4   Max: 0
Current: -9.6

-15.4
0

Analyst Estimate

Jun15 Jun16 Jun17 Jun18
Revenue(Mil) 106 75 71 87
EPS($) -0.64 -1.24 -1.30 -1.15
EPS without NRI($) -0.64 -1.24 -1.30 -1.15

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:IMU.Germany,
Immunogen Inc was incorporated in 1981, in Massachusetts. The Company is a biotechnology company that develops targeted anticancer therapeutics. It has developed its ADC technology to enable the creation of anticancer products. The Company develops its own product candidates using its ADC technology. It has three wholly owned, clinical-stage anticancer compounds: IMGN853, IMGN289, and IMGN529. It's IMGN853 product candidate is used for the treatment of ovarian cancer, endometrial cancer, and potentially other cancers that highly express folate receptor a, or FRa. It's EGFR-targeting ADC, IMGN289, is used for the treatment of cancers that highly express EGFR which include squamous cell carcinoma of the head and neck, or SCCHN, and types of non-small cell lung cancer (NSCLC), including both squamous cell and non-squamous cell NSCLCs. It's IMGN529 ADC is used for the treatment of cancers that highly express CD37, such as non-Hodgkin lymphoma, or NHL, and chronic lymphocytic leukemia. The Company's main competitors include Pfizer, Seattle Genetics, Roche and Bristol-Myers Squibb. In addition to regulations in the U.S., the company is subject to a variety of foreign regulations governing clinical trials and commercial sales and distribution of its products.
» More Articles for IMGN

Headlines

Articles On GuruFocus.com
Cowen & Co Remains Bullish on Celldex Therapeutics Following FDA 'Breakthrough' Approval Feb 24 2015 
Gulf Resources (GURE) Soars on Natural Gas Discovery, ImmunoGen (IMGN) and Synaptics (SYNA) Surge on Jan 31 2015 
Will ImmunoGen’s Q4 Earnings Disappoint Again? Jul 30 2014 
Murray Stahl’s $6.4 Billion Horizon Kinetics Sells Out Six Companies in First Quarter May 28 2013 
ImmunoGen Inc. Reports Operating Results (10-Q) Feb 08 2011 
ImmunoGen Inc. Reports Operating Results (10-Q) Oct 29 2010 
ImmunoGen Inc. Reports Operating Results (10-K) Aug 27 2010 
ImmunoGen Inc. Reports Operating Results (10-Q) Apr 30 2010 
ImmunoGen Inc. Reports Operating Results (10-Q) Jan 29 2010 
ImmunoGen Inc. Reports Operating Results (10-Q) Nov 04 2009 


More From Other Websites
Will Pharmaceutical Sales Drive J&J (JNJ) Earnings Again? - Analyst Blog Apr 13 2015
Lightning Round: Don't mess with this CEO Apr 09 2015
ImmunoGen, Inc. Announces Conference Call to Discuss its Third Quarter Fiscal Year 2015 Financial... Apr 09 2015
IMMUNOGEN INC Files SEC form 8-K, Other Events Apr 03 2015
ImmunoGen (IMGN) in Focus: Stock Rises 5.1% in Session - Tale of the Tape Apr 01 2015
ImmunoGen, Inc. Appoints Anna Berkenblit, MD, MMSc Vice President and Chief Medical Officer Apr 01 2015
Canaccord Hot And Cold On Deals By Teva Pharmaceutical, ImmunoGen Mar 31 2015
Immunogen (IMGN) Stock Gains Today After Selling Kadcyla Royalty Rights for $200 Million Mar 31 2015
IMMUNOGEN INC Files SEC form 8-K, Entry into a Material Definitive Agreement Mar 30 2015
ImmunoGen, Inc. Announces $200 Million Non-Dilutive Royalty Transaction Mar 30 2015
IMMUNOGEN INC Files SEC form 8-K, Entry into a Material Definitive Agreement Mar 26 2015
US STOCKS-Wall St little changed as energy retreats Mar 23 2015
US STOCKS-Wall St little changed as energy retreats Mar 23 2015
Takeda deal affords ImmunoGen both cash and credibility boost Mar 23 2015
US STOCKS-Wall St little changed as energy pares gains Mar 23 2015
ICYMI: Pharmaceutical Stocks Are Moving Big On Monday Mar 23 2015
ImmunoGen (IMGN) Stock Gains Today on Japanese Licensing Agreement Mar 23 2015
US STOCKS-Stocks up as dollar adds to losses, oil gains Mar 23 2015
US STOCKS-Wall St to dip at the open after weekly gains; volatility eyed Mar 23 2015
ImmunoGen lands big licensing deal with Japan's Tekada Mar 23 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK